{"id":"W3005289851","doi":"10.1038/s41375-020-0718-z","title":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)","year":2020,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"Cilag; National Cancer Institute; Pharmacyclics; Chugai Pharmaceutical; Janssen Research and Development; National Institutes of Health; Glenmark Pharmaceuticals; Adaptive Biotechnologies; Array BioPharma; Yale University; Raymond and Beverly Sackler Institute for Biological, Physical and Engineering Sciences, Yale University; Sanofi; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Winship Cancer Institute; Pfizer; Memorial Sloan-Kettering Cancer Center; Multiple Myeloma Research Foundation","keywords":"Clinical endpoint; Medicine; Dosing; Internal medicine; Multiple myeloma; Gastroenterology; Confidence interval; Phases of clinical research; Surgery; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003838936,0.0005753596,0.001429735,0.0001433906,0.0003916318,0.0001956401,0.0005203561,0.0001209098,0.0001608851],"category_scores_gemma":[0.001489662,0.0003631,0.0001526171,0.0003300269,0.0001658735,0.0003550908,0.0002829898,0.0005107689,0.00006774451],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005580764,"about_ca_system_score_gemma":0.0003394268,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002004313,"about_ca_topic_score_gemma":0.0004302669,"domain_scores_codex":[0.9964432,0.0003825384,0.0007421247,0.0009865039,0.0006560252,0.0007896594],"domain_scores_gemma":[0.9970429,0.0008640563,0.0004341663,0.0006318291,0.0002716604,0.0007553698],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7024389,0.007071707,0.204103,0.0001163702,0.002080667,0.0002521951,0.001864806,0.00001147372,0.00008692035,0.000001699294,0.0005810393,0.08139121],"study_design_scores_gemma":[0.9198195,0.0196412,0.02799451,0.0001506359,0.0007747966,0.000003060257,0.0005580549,0.02912067,0.000809122,0.000006044271,0.0007191169,0.0004032473],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9805763,0.0001168688,0.002263309,0.0001314158,0.0001870326,0.01595764,0.0005686826,0.0001559583,0.00004273275],"genre_scores_gemma":[0.9876127,0.0002160159,0.00850839,0.0004352852,0.0002008409,0.002182068,0.0005083942,0.0001511728,0.0001851332],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2173807,"threshold_uncertainty_score":0.9998821,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03634479394324643,"score_gpt":0.3299823469909974,"score_spread":0.293637553047751,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}